Colorado DJ’s suit against Taylor Swift dismissed in groping trial

DENVER (Reuters) – Pop star Taylor Swift on Friday won an important ruling in the trial stemming from her allegation that she was groped by a Colorado disc jockey, with the judge dismissing the DJ’s rival claim accusing the singer of wrongfully getting him fired. The ruling by U.S. District Judge William Martinez left intact Swift’s assault and battery countersuit against David Mueller, who asserts he was falsely accused by the recording star and ousted from his $150,000-a-year job at radio station KYGO-FM under pressure from her. The Grammy-winning artistRead More

Jury deliberations at Bill Cosby’s sex assault trial enter third day | Reuters

By Joseph Ax | NORRISTOWN, Pa. NORRISTOWN, Pa. Jurors at Bill Cosby’s sexual assault trial were scheduled for more deliberations on Wednesday after failing to reach a verdict after two days of discussions that stretched into the night. Cosby, 79, is accused of drugging and sexually assaulting Andrea Constand at his suburban Philadelphia home in 2004. The jury began deliberating Cosby’s fate late on Monday afternoon following a six-day trial in Norristown, Pennsylvania. Approximately 60 other women have made similar allegations against the former star of the hit 1980s TVRead More

Bayer, J&J win second U.S. trial over Xarelto bleeding risks | Reuters

A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the second trial to stem from thousands of lawsuits blaming injuries on the blood thinner Xarelto, the drug companies said on Monday. (Reporting by Nate Raymond in Boston; Editing by Dan Grebler) ‘); $(‘.second-article-divide’).append($(‘.slider.slider-module’)); $(‘.third-article-divide’).append(”); var median = (relatedItemsTotal / 2); var $relatedContentGroupOne = $(‘ ul’); var $relatedContentGroupTwo = $(‘ ul’); $.each($relatedItems, function(k,v) { if (k + 1 Also In Health News Source link

AbbVie’s rheumatoid arthritis drug succeeds in late-stage trial | Reuters

U.S. drugmaker AbbVie Inc said on Wednesday its drug to treat moderate-to-severe rheumatoid arthritis met the main goal in a late-stage study. Two doses of the drug, upadacitinib, were compared against a placebo in the 12-week long study, AbbVie said. (Reporting by Divya Grover in Bengaluru; Editing by Sai Sachin Ravikumar) ‘); $(‘.second-article-divide’).append($(‘.slider.slider-module’)); $(‘.third-article-divide’).append(”); var median = (relatedItemsTotal / 2); var $relatedContentGroupOne = $(‘ ul’); var $relatedContentGroupTwo = $(‘ ul’); $.each($relatedItems, function(k,v) { if (k + 1 Also In Health News Source link